ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kern, D.
Right arrow Articles by Hildebrand-Zanki, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kern, D.
Right arrow Articles by Hildebrand-Zanki, S.
Annals of Clinical and Laboratory Science, Vol 17, Issue 6, 383-388
Copyright © 1987 by Association of Clinical Scientists

Articles

Clinical application of the thymidine incorporation assay

DH Kern, VK Sondak, CR Morgan, and SU Hildebrand-Zanki

An improved method for testing human tumors against chemotherapeutic agents was developed. Drug effects were quantitated in the thymidine incorporation assay (TIA) by measuring inhibition of deoxyribonucleic acid (DNA) synthesis by the proliferating cell population following exposure to anticancer drugs. Results were obtained within five days. A total of 480 out of 568 tumors received were evaluable for an overall growth rate of 85 percent. Even small biopsy specimens could be successfully grown. In 126 correlations with clinical response, the TIA had a prediction accuracy for sensitivity of 51 percent and a prediction accuracy for resistance of 97 percent. Because it is rapid, has a high growth rate, and is not subject to clumping and other cellular artifacts, the TIA represents a significant improvement over colony counting assays for predicting drug effects in human tumors.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the Association of Clinical Scientists.